Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
BeiGene Australia Pty Ltd
Scientific Title
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors